Patents by Inventor Rene LEBL

Rene LEBL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for synthesis of quinazoline compounds
    Patent number: 12071422
    Abstract: Provided herein are methods to synthesize compounds useful in the treatment of cancer where such compounds comprise a quinazolinyl core moiety and at least one stereoisomeric or atropisomeric moiety.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: August 27, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Rene Lebl, Ngiap Kie Lim, Roland Christoph Meier, Ugo Jonathan Orcel, Joerg Sedelmeier, Jeff Shen, Lauren Elizabeth Sirois, Jacob C. Timmerman, Etienne Trachsel, Nicholas Andrew White, Jie Xu, Haiming Zhang, Stephan Bachmann, Thomas Michael Bass, Raphael Bigler, Johannes Adrian Burkhard, Kyle Bradley Pascual Clagg, Francis Gosselin, Chong Han, Dainis Kaldre, Sean M. Kelly, Sebastian Herold, Christian Leitner
  • PROCESS FOR PREPARING BTK INHIBITORS
    Publication number: 20240132508
    Abstract: Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3?-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4?]bipyridinyl-2?-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided.
    Type: Application
    Filed: November 3, 2023
    Publication date: April 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan BACHMANN, Lukas CHYTIL, Serena Maria FANTASIA, Alec FETTES, Ursula HOFFMANN, Christian Oliver KAPPE, Rene LEBL, Kurt PUENTENER, Paolo TOSATTI, Jason Douglas WILLIAMS
  • PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS
    Publication number: 20230250074
    Abstract: Provided herein are methods to synthesize compounds useful in the treatment of cancer where such compounds comprise a quinazolinyl core moiety and at least one stereoisomeric or atropisomeric moiety.
    Type: Application
    Filed: February 3, 2023
    Publication date: August 10, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Rene LEBL, Ngiap Kie LIM, Roland Christoph MEIER, Ugo Jonathan ORCEL, Joerg SEDELMEIER, Jeff SHEN, Lauren Elizabeth SIROIS, Jacob C. TIMMERMAN, Etienne TRACHSEL, Nicholas Andrew WHITE, Jie XU, Haiming ZHANG, Stephan BACHMANN, Thomas Michael BASS, Raphael BIGLER, Johannes Adrian BURKHARD, Kyle Bradley Pascual CLAGG, Francis GOSSELIN, Chong HAN, Dainis KALDRE, Sean M. KELLY, Sebastian HEROLD, Christian LEITNER